Balt International has announced receiving the CE mark for Magic Glue, its next generation of cyanoacrylate liquid embolic agent. Magic Glue is indicated for the embolization of arteriovenous malformations.
Magic Glue is a class III implantable medical device which is described as an arterial and venous embolization implant due to its haemostatic action, and is applicable in the fields of neuroradiology and interventional radiology. This medical device is applied in solution with a contrast agent.
“We are excited to enlarge our offer in the treatment of arteriovenous malformations with Magic Glue. This cyanoacrylate glue offers new features compared to the historical glues on the market such as delayed polymerisation and less adhesion to the microcatheter. These characteristics will facilitate and expand cyanoacrylate indication in the neurovascular and peripheral fields,” said Nicolas Plowiecki, president of Balt.
“Balt is again expanding its embolization portfolio with a new cyanoacrylate solution that provides another treatment option for neurovascular and peripheral physicians. We were among the first to enter the arteriovenous malformations market with the Magic flow-dependent microcatheter. Thirty years later, BALT keeps on delivering innovative solutions for better patient treatments,” commented Pascal Girin, CEO of Balt and president of Balt International.
